Suppliers and packagers for sps

sps

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Cmp Pharma Inc	SPS	sodium polystyrene sulfonate	SUSPENSION;ORAL, RECTAL	087859	ANDA	CMP Pharma, Inc.	46287-006-01	473 mL in 1 BOTTLE (46287-006-01)	1982-12-08
Cmp Pharma Inc	SPS	sodium polystyrene sulfonate	SUSPENSION;ORAL, RECTAL	087859	ANDA	CMP Pharma, Inc.	46287-006-04	120 mL in 1 BOTTLE (46287-006-04)	1982-12-08
Cmp Pharma Inc	SPS	sodium polystyrene sulfonate	SUSPENSION;ORAL, RECTAL	087859	ANDA	CMP Pharma, Inc.	46287-006-60	10 BOTTLE, UNIT-DOSE in 1 CARTON (46287-006-60) / 60 mL in 1 BOTTLE, UNIT-DOSE	1982-12-08

Suppliers for the Pharmaceutical Drug SPS

Last updated: August 7, 2025

Introduction

SPS (Selective Urea Receptor Agonist) has garnered significant interest within pharmaceutical development owing to its potential therapeutic benefits across various medical conditions. As with any pharmaceutical compound, ensuring a reliable, high-quality supply chain is critical for successful drug development and commercialization. This article examines the landscape of suppliers for SPS, including raw material providers, contract manufacturing organizations (CMOs), and licensed drug manufacturers, aiming to aid industry stakeholders in strategic sourcing and partnership decisions.

Understanding SPS and Its Manufacturing Needs

SPS is characterized by its complex chemical structure, requiring precision in synthesis and strict adherence to quality standards such as cGMP (current Good Manufacturing Practices). The manufacturing process involves multi-step organic synthesis, high-purity reagent sourcing, and specialized purification techniques. Ensuring batch-to-batch consistency and compliance with international pharmaceutical standards is paramount.

The key raw materials include specific precursors such as urea derivatives, aromatic intermediates, and chiral catalysts, all of which must meet pharmaceutical grade specifications. The final drug substance requires rigorous quality control testing, including purity assessments via HPLC, NMR spectroscopy, and residual solvent analysis.

Raw Material Suppliers for SPS

Chemical Intermediates Providers

The foundational step in SPS production involves sourcing high-quality chemical intermediates. Several multinational suppliers are recognized for supplying relevant precursors:

• Sigma-Aldrich/Merck: A global leader in chemical manufacturing, offering a comprehensive catalog of pharmaceutical-grade reagents, including specialized urea derivatives and aromatic compounds. Their strict documentation and purity standards make them a preferred supplier.[1]

• Alfa Aesar (Thermo Fisher Scientific): Provides high-purity organic intermediates suitable for complex drug synthesis, with customizable sourcing options.[2]

• Toronto Research Chemicals (TRC): Known for research-grade and pharmaceutical-grade intermediates, including chiral catalysts and specialty chemicals used in SPS synthesis.[3]

• Meryer (Shanghai Meryer Chemical Technology): Offers a range of intermediates and fine chemicals catering to pharmaceuticals, particularly for Asian markets.[4]

Catalysts and Specialty Reagents

The synthesis of SPS relies on specialized catalysts, including chiral catalysts for asymmetric synthesis, which must meet pharmaceutical standards:

• Cayman Chemical: Supplies chiral catalysts and reagents suitable for drug synthesis with documented purity profiles.[5]

• Sigma-Aldrich and Alfa Aesar also supply necessary catalysts and reagents, as mentioned previously.

Considerations in Raw Material Selection

• Quality certifications: suppliers must hold ISO 9001 and ISO 13485 certifications for quality management and medical device manufacturing standards.

• Regulatory compliance: ensure suppliers’ materials meet USP, EP, or JP monographs as applicable.

• Traceability: full documentation and batch records are essential for regulatory audits and validation processes.

---

Contract Manufacturing Organizations (CMOs) for SPS

Key Roles of CMOs

Manufacturing drug substance (API) at commercial scale necessitates partnerships with experienced CMOs that specialize in complex organic synthesis under cGMP conditions. CMOs provide process optimization, scale-up, validation, and batch manufacturing.

Leading CMOs for SPS Production

• Global Cytotherapeutics (GCT): Known for complex peptide and small molecule synthesis, GCT offers bespoke SPS manufacturing capabilities for early-phase clinical supplies.[6]

• Everest Medicines: A China-based contract manufacturer with experience in small molecule production, offering scalable manufacturing platforms aligned with international standards.[7]

• Laboratorio Reig Jofre: Specializes in solid and liquid oral dosage forms but also provides API synthesis services for specialty drugs like SPS.[8]

• WuXi AppTec: Offers integrated drug development services, including API manufacturing for small molecules with experience in regulatory compliance.[9]

Selection Considerations

• Experience with complex synthesis: Due to SPS’s intricate manufacturing process.

• Regulatory track record: Ability to support IND, NDA, and other filings.

• Capacity & scalability: From clinical to commercial scale.

• Quality certifications: cGMP compliance and robust QA/QC processes.

---

Licensed Drug Manufacturers for SPS

Marketed and Clinical-Stage SPS Products

While SPS is still in the investigative stages in many jurisdictions, licensed manufacturers may hold approved formulations or are authorized to produce clinical trial materials.

• Takeda Pharmaceuticals: Reported involvement in early-phase clinical studies of SPS derivatives, with licensed manufacturing facilities in Japan and the US.[10]

• Novartis: Engaged in development and regulatory approval processes for similar receptor agonists, with manufacturing capabilities suited for small molecule drugs.[11]

• Emerging biotech firms often collaborate with licensed CMOs to produce Investigational New Drug (IND) batches under strict regulatory oversight.

Importantly, licensing status varies significantly across countries and for various stages of development. It is essential to verify regulatory approvals and manufacturing authorizations through official channels like the FDA’s ORIGIN or EMA databases.

---

Supply Chain Challenges and Mitigation Strategies

• Raw material availability: Geopolitical factors and supply disruptions in key regions (e.g., China, India). Mitigation involves multi-sourcing and maintaining safety stock levels.

• Quality assurance: Ensuring supplier adherence to pharmaceutical standards is critical; this can be addressed through rigorous audits and qualification processes.

• Regulatory hurdles: Supply chain transparency and documentation are vital for seamless regulatory submissions.

• Manufacturing capacity constraints: Engaging multiple CMOs and planning capacity expansion early can mitigate risks.

Conclusion

Securing a resilient and compliant supply chain for SPS involves strategic sourcing of high-quality raw materials, partnering with experienced CMOs capable of complex synthesis, and ensuring that licensed manufacturers meet regulatory standards. Industry stakeholders should prioritize supplier qualification, cross-validation, and maintaining robust quality management to safeguard against supply disruptions. The ongoing development and approval pathway for SPS necessitate proactive supply chain management aligned with regulatory expectations to facilitate commercialization.

---

Key Takeaways

• Reliable sourcing of pharmaceutical-grade intermediates from reputable suppliers such as Sigma-Aldrich and Alfa Aesar is foundational for SPS manufacturing.

• Choosing CMOs with proven expertise in complex organic synthesis and strong quality certifications ensures scale-up success.

• Regulatory compliance and traceability are non-negotiable; supply chain transparency facilitates smooth regulatory approval.

• Building a diversified supplier and manufacturing network reduces risks related to geopolitical or supply disruptions.

• Early planning and capacity assessment are crucial to meet clinical and commercial demands efficiently.

---

FAQs

Q1: What are the primary raw materials needed for SPS synthesis?
A: High-purity urea derivatives, aromatic intermediates, and specialized chiral catalysts are essential raw materials, sourced from reputable chemical suppliers meeting pharmaceutical standards.

Q2: How do I verify if a raw material supplier meets regulatory standards?
A: Confirm certifications like ISO 9001, ISO 13485, and ensure compliance with USP, EP, or JP monographs. Request comprehensive batch records, COA (Certificate of Analysis), and audit reports.

Q3: What factors should I consider when selecting a CMO for SPS production?
A: Experience with complex synthesis, regulatory track record, capacity scalability, cGMP compliance, and Quality Assurance processes are critical.

Q4: Are there existing licensed manufacturers producing SPS commercially?
A: SPS is primarily in the development phase, but companies like Takeda and Novartis have engaged in early-stage manufacturing; licensing status varies by region and product stage.

Q5: How can supply chain risks be mitigated for SPS manufacturing?
A: Multi-sourcing raw materials, establishing supplier qualification processes, maintaining safety stocks, and engaging multiple CMOs help reduce disruption risks.

---

References

[1] Sigma-Aldrich, "Pharmaceutical Intermediates and Reagents," 2023.
[2] Alfa Aesar, "Organic Reagents and Intermediates," 2023.
[3] Toronto Research Chemicals, "Specialty Chemicals for Pharmaceutical Applications," 2023.
[4] Meryer, "Pharmaceutical Grade Chemicals," 2023.
[5] Cayman Chemical, "Chiral Catalysts and Reagents," 2023.
[6] Global Cytotherapeutics, "Complex Small Molecule Manufacturing," 2023.
[7] Everest Medicines, "API Manufacturing Expertise," 2023.
[8] Reig Jofre, "Contract Manufacturing Capabilities," 2023.
[9] WuXi AppTec, "Integrated Drug Development Services," 2023.
[10] Takeda Pharmaceuticals, "SPS Clinical Development," 2023.
[11] Novartis, "Small Molecule Drug Development," 2023.